XML 65 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2021
Stock-Based Compensation  
Schedule of assumptions used to determine the grant-date fair value of stock options

The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted:

    

Year Ended December 31, 

 

    

2021

    

2020

 

Risk-free interest rate

1.1

%  

0.4

%

Expected volatility

 

65

%  

60

%

Expected dividend yield

 

 

Expected term (in years)

 

6

 

6

Schedule of option activity

The following table summarizes the Company’s option activity for the fiscal year ended December 31, 2021:

Weighted

Average

Weighted

Aggregate

Number

Exercise

Contractual

Intrinsic

    

of Shares

    

Price

    

Term

    

Value

(in years)

(in thousands)

Outstanding at beginning of period

3,405,698

$

2.27

7.1

$

186,234

Granted

 

65,256

36.89

Exercised

 

(671,661)

1.33

 

  

 

  

Forfeited

 

(52,252)

2.19

 

  

 

  

Outstanding at end of period

 

2,747,041

$

3.32

 

6.7

$

62,714

Vested and expected to vest at end of period

 

2,682,327

$

3.27

 

6.6

$

61,353

Exercisable at end of period

 

1,766,726

$

2.01

 

5.7

$

42,324

Schedule of restricted stock unit activity

The following table summarizes the Company’s restricted stock units activity for the fiscal year ended December 31, 2021:

Weighted

Average

Number

Grant Date

    

of Shares

    

Fair Value

Unvested at beginning of period

$

Granted

 

197,669

 

36.43

Vested and released

 

(174)

 

57.47

Forfeited

 

(9,731)

 

46.78

Unvested at end of period

 

187,764

$

35.87

Schedule of stock-based compensation expense

The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss (in thousands):

Year Ended December 31, 

2021

    

2020

Cost of revenue

$

97

$

37

Research and development expenses

448

 

129

Selling, general and administrative expenses

1,959

 

359

$

2,504

$

525